Understand the source comparison
ARA-290 vs Other Research Peptides: Type Comparison
ARA-290 EPOR-βcR tissue-protective receptor activation Neuropathy, autoimmune cytoprotection, metabolic stress 1–8mg SC 3×/week 8–12 hours Anti-apoptotic, not regenerative. Best for cell survival under metabolic stress BPC-157 VEGF upregulation, FAK pathway ac
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- ARA-290
- EPOR-βcR tissue-protective receptor activation
- Neuropathy, autoimmune cytoprotection, metabolic stress
- 1–8mg SC 3×/week
- 8–12 hours
- Anti-apoptotic, not regenerative. Best for cell survival under metabolic stress
- BPC-157
- VEGF upregulation, FAK pathway activation
- Tendon/ligament repair, GI ulceration, vascular injury
- 200–500mcg SC/IM daily
- 24–48 hours
- Accelerates structural tissue repair and angiogenesis. Primary injury recovery tool
- TB-500 (Thymosin Beta-4)
- G-actin sequestration, cell migration facilitation
- Wound healing, cardiac repair, hair follicle stimulation
- 2–5mg SC 2×/week
- Multi-day stability
- Promotes cell migration and tissue remodeling. Effective for chronic degenerative repair
- GHK-Cu
- Gene expression modulation, antioxidant enzyme activity
- Skin remodeling, collagen synthesis, wound closure
- 1–3mg topical or SC
- 12–24 hours
- Matrix remodeling and antioxidant effects. Cosmetic and dermatological research focus
- Selank
- BDNF modulation, monoamine system regulation
- Anxiety reduction, cognitive enhancement, immune modulation
- 250–750mcg intranasal daily
- 20–30 minutes
- Anxiolytic and nootropic. No tissue repair or metabolic stress applications
- Semax
- BDNF upregulation, cerebral circulation improvement
- Cognitive function, stroke recovery, neuroprotection
- 300–600mcg intranasal daily
- 60–90 minutes
- Nootropic and neuroprotective. Cerebral applications only, no peripheral tissue effects
- ARA-290's unique tissue-protective mechanism without hematopoietic side effects positions it for conditions where other peptides lack targeted efficacy. Particularly diabetic neuropathy and autoimmune-mediated cellular stress.